Mannose-binding lectin (MBL) is a C-type lectin involved in the ®rst line of host defense and it requires MBL-associated serine proteases (MASP) for activation of the lectin complement pathway (LCP). Recently we reported that human ®colins, L-®colin/P35 and H-®colin/Hakata antigen, as well as MBL activate the LCP in association with MASP. We investigated in vitro expression of complements of the lectin complement pathway in several cell lines. Out of 17 cell lines tested using RT-PCR, a human glioma cell line, T98G, expressed high levels of H-®colin/Hakata antigen, MASP1 and MASP3 mRNAs. Similar results were obtained in four other glioma lines. In addition, mRNAs for C1r, C1s, C2, C3, C4, C5 and C6 were also detected in T98G cells, but very low amount of mRNAs for C1q and MBL. MBL mRNA was seen in two of the other glioma cell lines. An ELISA of culture supernatants showed that T98G cells secreted a considerable amount of MASP-1 and MASP-3 proteins. SDS±PAGE and immunoblotting analyses showed the secreted H-®colin/Hakata antigen, MASP-1 and MASP-3 to be 34, 81 and 105 kDa in size respectively, similar to their serum counterparts. Since the glioma cells used are derived from astrocytes, this suggests that human astrocytes may be a source of some components of the LCP in the brain.
Introduction
The complement system in blood functions as a major mediator of innate immune defense against invading microorganisms. It is activated in three ways via the classical, the alternative and the lectin complement pathways (LCP). The LCP is an antibody-independent cascade initiated by the binding of mannose-binding lectin (MBL) and its associated enzymes (MBL-associated) serine proteases (MASP) to cellsurface carbohydrate moieties (1) . The molecular interactions leading to MASP activation are not clearly understood. MASP probably bind close to the N-terminal region of the collagenlike domain of MBL (2) . This region of MBL forms a central core that links trimeric subunits to form bouquet-like oligomers. Three types of human MASP (MASP-1, MASP-2 and MASP-3) have been identi®ed (3±6). MASP-1 was identi®ed as a C1r/ C1s-like serine protease which weakly cleaves C2 and C3 (7±9). Subsequently, MASP-2, with high homology to MASP-1, was isolated, and shown to activate complement via cleavage of C2 and C4 (5) . These substrate speci®cities between MASP-1 and MASP-2 were con®rmed using the recombinant proteins (9) . Although the MBL±MASP-2 complex containing small MBL-associated protein sMAP works ef®ciently on the LCP activation, most probably MASP-1 could be also involved in the LCP with cleaving activities of C2 and C3. Recently, MASP-3 was isolated from plasma and cloned by PCR, and shown to consist of the same heavy chain/A chain as MASP-1, but a different light chain/B chain (6) . Thus, MASP-1 and MASP-3 may have both shared and unique features. MASP1, MASP2 and MASP3 mRNAs are expressed mainly in liver, and the resulting proteins are secreted into the blood. MASP are not only associated with MBL, but also form complexes with members of the ®colin family proteins, L-®colin/P35 and H-®colin/Hakata antigen, and ®colin±MASP complexes are capable of activating the LCP (7, 10, 11) . The ®colin polypeptide chain consists of a short N-terminal domain, a middle collagen-like domain that forms a triple helix and a C-terminal ®brinogen-like domain (12, 13) . These structural features are very similar to those of the collectins, such as MBL, conglutinin, collectin-43, and surfactant proteins A and D (13, 14) , but for the presence of a C-type carbohydrate recognition domain in the collectins. Ficolins have been identi®ed in mammals, including human (13,16±18), rodents (19) , pig (12, 20) and hedgehog (21) with tissue-speci®c distributions. They are also identi®ed in the invertebrate, ascidian (Halocynthia roretzi) (22) . Thus, in addition to MBL, L®colin/P35 and H-®colin/Hakata antigen were involved in LCP activation.
There are indications that neurons are one of the most abundant sources of complement components (23±25) and it is thought that neurons are responsible for local immunity by producing these proteins. We think it is possible that the LCP also plays an important role in local immunity in the brain.
To assess the importance of the LCP in local immunity, a variety of cell lines were tested for expression of complement proteins by RT-PCR. In this study, we focus particularly on glioma cell lines as a model for nerve cells and we discuss the signi®cance of the LCP components (MASP and ®colins) in the brain.
Methods

Antibodies
Monospeci®c polyclonal anti-C2, -C3 and -C4 antibodies were obtained by immunization of rabbits with the respective puri®ed human proteins. Rabbit polyclonal anti-C1r and -C1s antibodies were obtained from Calbiochem (Darmstadt, Germany), and goat polyclonal anti-C5 and -C6 antibodies from Serotec (Oxford, UK) and Cytotec (San Diego, CA) respectively. Monoclonal anti-MASP1/3 antibodies 1E2 and 2B11 were described previously (26) . Hybridomas producing anti-H-®colin/Hakata antigen antibody (4H5) and rabbit polyclonal anti-H-®colin/Hakata antigen antibody were kindly provided by Dr N. Hamasaki (Kyushu University, Fukuoka, Japan). Rabbit polyclonal anti-MASP-3 antibody was prepared by immunizing with the peptide containing the Cterminal 20 amino acids of MASP-3 light chain. Biotin-conjugated rabbit anti-mouse Ig, biotin-conjugated goat anti-rabbit Ig and biotin-conjugated swine anti-goat Ig were purchased from Dako Japan (Kyoto, Japan).
To con®rm the speci®city of 1E2, 2B11 and anti-MASP-3 antibodies, an immunoblot analysis was performed (Fig. 1) . The serum fraction containing MASP-1 and MASP-3 was prepared as described elsewhere (7) . 1E2, 2B11 and anti-MASP-3 antibodies all reacted with serum-derived MASP-3. 1E2 and 2B11 further reacted with MASP-1, suggesting that 1E2 and 2B11 recognizes the heavy chain, which MASP-1 shares with MASP-3. The weaker staining of MASP-3 than of MASP-1 in the ®gure is due to the presence of more MASP-1 than MASP-3 on the blot.
Cell lines
The characteristics and sources of the cell lines used are given in Table 1 . Cells were grown in 5% CO 2 at 37°C in RPMI 1640 supplemented with 10% heat-inactivated FCS, 100 U/ml streptomycin and 100 U/ml penicillin.
Human liver sample
Human liver was resected surgically due to the presence of a hepatoma. The sample used was obtained from a portion unaffected by the cancer. The prepared liver sample expressed the tested components except M-®colin/P35-related and was used as a positive control.
Preparation of monocytes
Brie¯y, human peripheral mononuclear cells were isolated from blood on Ficoll-conray gradients (27) and monocytes were separated from lymphocytes by adherence to plastic culture dishes (28) . The adherent cells were used as monocytes.
Extraction of total RNA and cDNA preparation Total RNAs were extracted from cells (cultured with FCS) by the guanidinum isothiocyanate method (29) , the concentrations were determined by absorbance at 260 nm and the RNAs were analyzed by electrophoresis on 1% agarose gels. cDNA was prepared from an equal amount of total RNA with Superscript II reverse transcription (Gibco/BRL) according to the supplier's protocol. A amount of 0.5 mg of total RNA per each sample was used equally.
RT-PCR
PCR was carried out using AmpliTaq DNA polymerase (Gibco/ BRL) according to the recommendations of the supplier. PCR primers used for MASP1, MASP2, MASP3, MBL, H-®colin/ Hakata antigen, L-®colin/P35, M-®colin/P35-related, C1r, C1s and G3PDH were designed using PRIMER3 software in BIOSUPPLYNET and are listed in Table 2 . The PCR conditions used for L-®colin/P35 and M-®colin/P35-related protein were as follows: 1 cycle of denaturation for 2 min at 94°C; ®ve cycles at 94°C for 30 s, annealing at 72°C for 1 min and extension at 68°C for 2 min; ®ve cycles at 94°C for 30 s, annealing at 70°C for 1 min and extension at 68°C for 2 min; 35 cycles at 94°C for 30 s, annealing at 68°C for 1 min and extension at 68°C for 2 min, and ®nal elongation at 68°C for 7 min. The PCR conditions used for MASP1, MASP2, MASP3, MBL, H-®colin/ Hakata antigen, C1r and C1s were as follows: 1 cycle of denaturation step for 2 min at 94°C; ®ve cycles at 94°C for 30 s, annealing at 65°C for 1 min and extension at 68°C for 2 min; ®ve cycles at 94°C for 30 s, annealing at 60°C for 1 min and extension at 68°C for 2 min; 35 cycles at 94°C for 30 s, annealing at 48°C for 1 min and extension at 68°C for 2 min, and ®nal elongation at 68°C for 7 min. PCR was performed in a PCR Thermal Cycler MP (Takara, Tokyo, Japan). PCR products were analyzed by electrophoresis on 2% agarose gel. Relative optical density units (shown in the ®gures) represent ethidium bromide gel band intensities as determined by quantitative analysis using Image software (Scion, Frederick, MD).
Detection of MASP-1 and MASP-3 by a sandwich ELISA
Aliquots of 100 ml of culture supernatant per well were used for detecting MASP-1 and MASP-3. The supernatants used were prepared in the presence of FCS because of no interference by FCS in the ELISA. A sandwich ELISA was performed using a published procedure (26) . The mAb (IE2 and 2B11) used recognize the heavy chain common to both MASP-1 and MASP-3. Thus, the ELISA indicates the sum of MASP-1 and MASP-3 proteins secreted (Fig. 1) . 8) . Prepared in the presence of FCS, even IE2-column-puri®ed MASP-1 and MASP-3 contained FCS-derived non-speci®c proteins, and the representative bands were not detected in the immunoblot analyses because of the higher concentration and similar sizes of FCSderived proteins. The supernatants were collected, centrifuged at 500 g for 10 min and ®ltered through a 0.22-mm ®lter.
The ®ltrate was used as T98G supernatant. T98G supernatants were concentrated 1000-fold using a Ultrafree-15 centrifugal ®lter device (Millipore, Bedford, MA) for immunoblotting of H®colin/Hakata antigen, C1r, C1s, C2, C3, C4 and C5. T98G supernatants (prepared without FCS) were applied to beads coupled with the monoclonal anti-MASP1/3 antibody IE2. After washing with 10 mM Tris±HCl, pH 8.0 containing 150 mM NaCl and 100 mM pefablock (Pentepharm AG, Basel, Switzerland), MASP-1 and MASP-3 were eluted with 50 mM glycine±HCl, pH 2.2 containing 150 mM NaCl. The eluates were neutralized with 1 M Tris±HCl, pH 8.0 and concentrated 1000-fold using a Ultrafree-15 centrifugal ®lter device. Aliquots of concentrated supernatants were electrophoresed on 7.5 or 10% SDS±PAGE slab gels under reducing conditions and electrotransferred onto Immobilon-P membranes (Millipore). The blots were saturated with Blockace (Dainippon, Osaka, Japan), incubated with primary antibody and with biotinconjugated secondary antibodies. After extensive washing, the blots were incubated with peroxidase-conjugated avidin± biotin complex (Vectastain ABC kit; Vector, Burlingame, CA). Finally the blots were developed using a Konica Immunostaining HRP-1000 Kit (Seikagaku, Tokyo, Japan).
Results
Detection of complement components by RT-PCR
RT-PCR was used to examine the constitutive expression of complement component mRNAs in human liver and peripheral monocytes. Primers designed for complement component (C1r, C1s, C1q, C2, C3, C4, C5, C6, C7, C8, C9, B, MASP1, MASP2, MASP3, MBL, L-®colin/P35, M-®colin/P35-related and H-®colin/Hakata antigen) mRNAs were used. G3PDH was included as an internal standard to ensure that the levels of cDNAs in the different samples were comparable. Figure 2 shows that the mRNAs of all the complement components, with the exception of M-®colin/P35-related, could be detected in human liver. M-®colin/P35-related could be detected in peripheral monocytes (used as a positive control of M-®colin/ P35-related). The sizes of all were consistent with those predicted (see Methods). The faint band in the C1q lane in T98G cells is an artifact. The levels of internal standard G3PDH mRNAs in the 21 tested lines and controls were comparable (Fig. 3A) , indicating that the levels of mRNAs detected re¯ect the cell-speci®c expression levels in the experiments.
Expression of MBL, L-®colin/P35, M-®colin/P35-related and H-®colin/Hakata antigen mRNAs
The expression of mRNAs for recognition molecules in the LCP was examined. To examine which type of cells express MBL, L-®colin/P35, M-®colin/P35-related and H-®colin/Hakata antigen mRNAs, RT-PCR was performed on 17 cell lines (Fig. 3B) . Expression of L-®colin/P35 and H-®colin/Hakata antigen mRNAs was detected in lymphoid, myeloid as well as nonmyeloid cells. In contrast, MBL mRNA expression was strongly observed in HepG2 and MT-2. M-®colin/P35-related mRNA expression was negligibly low in all the cell lines tested. In T98G cells, a relatively high level of H-®colin/Hakata antigen mRNA was detected, whereas the other lectin mRNAs were at low levels. MBL, L-®colin/P35 and H-®colin/Hakata antigen mRNAs are detected in human liver, but not M-®colin/P35-related, while M-®colin/P35-related mRNA was detectable in normal peripheral monocytes. 
Expression of MASP1, MASP2, MASP3, C1r and C1s mRNAs
To study which type of cells express MASP1, MASP2, MASP3, C1r and C1s mRNAs, RT-PCR was performed with 17 cell lines ( Fig. 3C and D) . MASP mRNAs were expressed broadly and at varying levels by 11 of the 17 cell lines (Fig. 3C ). There was a tendency for non-lymphoid, non-myeloid lines such as T98G, TKB1, HepG2 and HeLa to express MASP1 and MASP3 mRNAs at relatively high levels, while lymphoid and myeloid lines (especially monocytic lines) expressed only negligible levels of MASP mRNAs. It was of interest that a glioma line, T98G, expressed MASP1 and MASP3 mRNAs at levels as high as liver, which is the main source of serum complement components. Of the cell lines tested, only HepG2 expressed MASP2 mRNA at a signi®cant level. It seems likely that hepatocytes are speci®c producers of MASP2. HeLa and TKB-1 also expressed relatively large amounts of MASP3 mRNA. The C1q-associated serine proteases, C1r and C1s, like MASP mRNAs, were broadly expressed (Fig. 3D) . Monocytic cell lines expressed lower levels of C1r and C1s mRNAs.
Expression of components of the LCP in glioma cell lines
The ®nding that T98G cells express high levels of MASP1 and MASP3 mRNAs suggests the possibility that the expression of the LCP components may be common characteristics for astrocytes. To assess this, four other glioma cell lines derived from astrocytes, A7, A172, 1321N1 and U251, were examined for expression of the mRNAs for components of the LCP. The results shown in Fig. 4(A) show that comparable levels of G3PDH mRNAs were recovered from the glioma lines. On the other hand, the glioma cell lines were found to express MASP1 and MASP3 mRNAs, but negligible amounts of MASP2 mRNA (Fig. 4C) . However, the levels of expression in A7, A172, 1321N1 and U251 cells were lower than in T98G cells. There was no similarity in the expression pattern of mRNAs for MBL, L-®colin/P35, M-®colin/P35-related and H-®colin/Hakata antigen, among the glioma lines (Fig. 4B) , with the exception that the expression of M-®colin/P35-related mRNAs was negligible in all of them. Of ®ve glioma lines tested, A172 and 1321N1 expressed MBL mRNA at a relatively high level. The results suggest that astrocytes express the components of the LCP.
Secretion of MASP-1 and MASP-3 proteins by glioma cell line T98G
To examine whether MASP-1 and MASP-3 proteins are secreted by T98G (MASP1 + /MASP2 ± /MASP3 + ), HeLa cells (MASP1 ± /MASP2 ± /MASP3 + ) and TKB-1 (MASP1 ± /MASP2 ± / MASP3 + ) consistent with their levels of mRNA expression, a sandwich ELISA was performed using the supernatants prepared with FCS (Fig. 5) . Since the mAb (1E2 and 2B11) against MASP-1 which we used recognize the heavy chain which is common to both MASP-1 and MASP-3, both of them are detected with this ELISA. As shown in Fig. 5 , T98G cells secreted signi®cant levels of MASP-1 and MASP-3, while HeLa and TKB-1 cells secreted only very low levels, suggesting that, in HeLa and TKB-1 cells, MASP-3 protein might be secreted only in response to certain stimuli.
The level of MASP-1/MASP-3 in serum was estimated to bẽ 6 mg/ml (26) and it was~3 mg/ml (~100 ng/10 6 cells/day) in the T98G supernatants prepared with FCS, suggesting similarly functional levels of production. Since T98G cells produce MASP-1/MASP-3 proteins, they could be good models for studying its production in the brain.
Isolation of MASP-1 and MASP-3 proteins from T98G culture supernatant
Since 1E2 recognizes both MASP-1 and MASP-3 (Fig. 1) , the above ELISA shows the combined production of MASP-1 and MASP-3. To con®rm that both MASP-1 and MASP-3 are produced by T98G and to de®ne the size of the MASP-3, MASP-1 and MASP-3 proteins were isolated from T98G supernatants by IE2-coupled Sepharose beads. Since FCS involvement in the supernatants gave non-speci®cally bound proteins in the af®nity chromatography, the supernatants were prepared without FCS (see Methods). The eluted material was analyzed by SDS±PAGE under non-reducing conditions (Fig. 6A) and immunoblotting (Fig. 6B and C) , which showed MASP-1 and MASP-3 to be 81 and 107 kDa respectively. A 107-kDa band was also immunostained by the anti-MASP-3 light chain C-terminal peptide antibody (Fig. 6C) . The obtained MASP-1 and MASP-3 were identical sizes to serum counterparts and would be functionally active. More MASP-3 than MASP-1 was secreted by the T98G cells in accordance with the relatively higher MASP3 mRNA expression.
Productive expression of C1r, C1s, C2, C3, C4, C5, C6 and H-®colin/Hakata antigen in T98G cells
Tested for expression of the lectin mRNAs, T98G cells expressed a clear level of mRNA for H-®colin/Hakata antigen and lower levels of other lectins as shown in Fig. 3 . Furthermore, we analyzed whether the T98G cells produce other relevant complement factors as control proteins. Using RT-PCR, C1r, C1s, C2, C3, C4, C5 and C6 mRNAs were detected at signi®cant levels in T98G cells (Fig. 7) , but no mRNA for C1q could be detected.
Thus, it would be expected that T98G cells produce these proteins as well as H-®colin/Hakata antigen in accordance with the expression of mRNAs. This was con®rmed by immunoblot analyses which revealed the secretion of C1r, C1s, C2, C3, C4, C5, C6 and H-®colin/Hakata antigen by T98G cells (Fig. 8) . The supernatants were prepared without FCS since comparably higher amounts and similar sizes of serum proteins interfere with the detection, and highly concentrated because of the lowered secretion by no FCS culture. It seems that at least the early complement components (except C1q) are produced at effective levels by T98G cells.
Discussion
Immunity is divided in innate and acquired immunities. The innate immune system seems to be older than the acquired immune system. The innate immune system is the older, more primitive recognition system with less speci®city. The complement system functions as the innate immune system to clear deleterious invaders. The blood±brain barrier is a major protective mechanism for the central nervous system against circulating bacteria. The brain cells can synthesize full lytic complement components and complement receptors (32), suggesting the importance of the complement system within the blood±brain barrier. It is known that the classical and the alternative complement pathways contribute to local immunity, which is probably the ®rst line of immune defense. However, little is known about the contribution of the LCP to local immunity. To address this, using RT-PCR we examined the expression of mRNAs for components of the LCP in a variety of cell lines. This analysis showed that the glioma cell line T98G expresses MASP1 and MASP3 mRNAs; ELISA and immunoblotting con®rmed that both proteins are synthesized and secreted by T98G cells. The estimated sizes of MASP-1 and MASP-3 were 81 and 107 kDa respectively. As MASP-3 in the T98G cells was found to be produced in larger amounts than MASP-1, it could be speculated that MASP-3 might have more important roles than MASP-1 in the brain. Productive expression of H-®colin/Hakata antigen by T98G cells was also observed, although, unexpectedly, very low MBL and MASP2 mRNA levels were detected in T98G cells. The early complement components were detected in T98G supernatants, but mRNAs for the late components were negligibly low. However, since human cerebrospinal¯uid contains enough C1 to C9 to give hemolytic activity (33) , and MASP-1 cleaves C2 and C3 (7±9), the LCP might still work within the blood±brain barrier. H-®colin/Hakata antigen was not detected in material from T98G cells puri®ed on anti-MASP-1/-3 antibodies, suggesting that H-®colin/Hakata antigen does not associate with MASP-1 and MASP-3 (not shown). There is still a chance that H-®colin/Hakata antigen can form a complex with MASP after H-®colin/Hakata antigen is bound to the surface of xenobiotics.
In this study, we focused on gliomas/astrocytes, but it is also very interesting that MASP3 mRNA was expressed at comparably high levels in HeLa and TKB-1 cells. MASP3 expression in these cell lines could contribute to local immunity in lung and cervix because they are located at the front line of the immune defense mechanism. We detected high levels of MASP2 mRNA only in HepG2, whereas the others tested express very low MASP2 mRNA levels. Thus, it is likely that MASP2 expression is restricted to hepatocytes. The differences in expression of MASP1, MASP2 and MASP3 probably re¯ect the functional differences of the derived proteins.
The present study shows that cells do not always express both lectin and MASP, although a complex of these is expected to be the initiating factor of the LCP. Although it is the MBL±MASP-2 complex that activates the LCP ef®ciently via C2 and C4 cleavages, T98G cells express very low MBL and MASP2 mRNAs levels, unexpectedly. Instead, the other combination, H-®colin/Hakata antigen±MASP-1/MASP-3, was obtained in T98G cells. The difference of the substrate speci®city between MASP-1 and MASP-2 is an activity in which C3 and C4 are mainly cleaved. It is likely that the molecular-evolutional appearance periods of MASP correlate with the periods of the substrate molecules (C3 and C4) (34) . From this point of view, C3 and MASP-1/MASP-3 molecules seem to be older than C4 and MASP-2 molecules, suggesting the LCP initiation consists of two steps dependent on the molecular evolution (C3/MASP-1 and C4/MASP-2). At present, MASP-3 function is unclear, but the high expression of MASP-3 in astrocytes indicates that MASP-3 is involved in other functions that could be important in the brain.
On the other hand, lectin mRNAs in the cell lines showed different expression spectra. L-®colin/P35 and H-®colin/ Hakata antigen are expressed broadly, whereas MBL mRNA is expressed in MT-2 and HepG2, and M-®colin/P35-related mRNA is negligibly low in all cell lines tested. Thus, the expression of MBL and M-®colin/P35-related is more restricted than H-®colin/Hakata antigen and L-®colin/P35. Expression of L-®colin/P35 and H-®colin/Hakata antigen in T, B and monocytic cell lines is expected to contribute to cellular immunity. Even in gliomas tested, variable expression of the lectins was obtained, suggesting that the ®ne differences (such as differentiation and activation) among the gliomas in¯uence the lectin expression. Lectins in themselves would be molecules independent of complement and might not always be regulated dependently on it. It would be acceptable that lectins as a recognition molecule are variably expressed since a variable lectin±MASP combination could possibly produce LCP activation (10, 11) . The important feature of a model cell line for studying the LCP would be to express at least both one of the three lectins (MBL, L-®colin/P35 and H-®colin/Hakata antigen) and either of MASP-1 and MASP-2.
In conclusion, human glioma T98G cells express H-®colin/ Hakata antigen, MASP-1 and MASP-3. This suggests that the LCP functions as a local innate immune system in the brain. It is expected that the role of the LCP components produced locally by HeLa and TKB1 as well as T98G is to work independently of serum components right at the invasion since cervix/HeLa and lung/TKB-1 locate at the front of the defense. MASP-1 seems to be the more primitive molecule to initiate the LCP than MASP-2. Within the blood±brain barrier, such primitive MASP-1(-3) would mainly work as local immunity. T98G cells should be convenient models for studying the production of MASP-1 and MASP-3 by human astrocytes in the central nervous system. It is anticipated that further studies will clarify the functions of MASP-3 in brain as well as in plasma.
